Research

Cellular

Tirzepatide is associated with a reduction in systolic arterial pressure by 4 to 6 mmHg and total cholesterol by 4–6% compared to baseline.

TZP may provide cardiovascular benefits in addition to glycemic control.

StrongSupportsmedium confidence
TZP has pleiotropic effects potentially dampening the individual cardiovascular risk, including a reduction in systolic arterial pressure by 4 to 6 mmHg and total cholesterol by 4–6% compared to baseline.
Giuseppe Lisco et al. · Endocrines · 2024

Why this rating

Based on data from human studies.

Source

Is Tirzepatide the New Game Changer in Type 2 Diabetes?

Giuseppe Lisco et al. · Endocrines · 2024

DOI 10.3390/endocrines5010005

reviewCited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →